Ashford Hospitality Prime Inc. (AHP)

10.44
0.27 2.52
NYSE : Finance
Prev Close 10.71
Open 10.69
Day Low/High 10.41 / 10.73
52 Wk Low/High 8.44 / 11.34
Volume 132.38K
Avg Volume 285.60K
Exchange NYSE
Shares Outstanding 32.12M
Market Cap 336.62M
EPS 0.50
P/E Ratio 20.35
Div & Yield 0.64 (6.17%)

Earnings at Schering-Plough, AHP Reflect Ongoing Sagas

Schering grapples with plant problems, and American Home sees more diet-drug litigation costs.

FDA Not Solely to Blame for Drug-Approval Delays

FDA Not Solely to Blame for Drug-Approval Delays

One analyst studied and ranked big pharmas on how long it takes to get a drug approved by regulators.

Investors Will Be Seeking Safety, but Not All Will Desert Biotech

An early move to big pharma is likely, then look for some shifting into better biotech.

Aviron Says Flu Drug Won't Be as Late as Feared

Aviron Says Flu Drug Won't Be as Late as Feared

The FDA won't require more trials of FluMist, so the nasal vaccine should arrive next year.

This Market's Hotties May Surprise You

Chemical stocks are cold as ice, but health care names are on fire.

American Home Products Misses Street Estimates by a Penny

American Home Products Misses Street Estimates by a Penny

The drugmaker reported second-quarter net income of 36 cents per share compared to 31 cents per share a year ago.

The Big Screen:  Health Care Funds That Make the Grade

The Big Screen: Health Care Funds That Make the Grade

Despite their recent performance, adding a health care fund to your portfolio can improve returns and reduce risk.

American Home Options Attract Interest

American Home Options Attract Interest

Big Pharmas Don't Feel the Slowdown's Pain

Big Pharmas Don't Feel the Slowdown's Pain

Bristol-Meyers, Pharmacia and American Home all report strong quarters.

American Home Hits Estimate

American Home Hits Estimate

Sector Spotlight: No Slowdown in Sickness, So Drugs Will Prove Steady Earners

Sector Spotlight: No Slowdown in Sickness, So Drugs Will Prove Steady Earners

Fundamentals remain strong for drug companies, with patent expirations the one worry.

The Daily Interview: A Non-Nasdaq Bull Market?

The Daily Interview: A Non-Nasdaq Bull Market?

Lord, Abbett's Robert G. Morris sees the S&P rising 21% in the coming months.

Drugs Feeling Poorly as Investors Finding Their Way Back to Techville

Drugs Feeling Poorly as Investors Finding Their Way Back to Techville

Johnson & Johnson and Merck are two of the Dow's few losers today.

The Big Screen: Leading Health Care Funds That Keep Costs Down

The Big Screen: Leading Health Care Funds That Keep Costs Down

It's been a tough year so far for the sector, but here are some smart bets.

American Home in Fat City Even as Charge Swells

American Home in Fat City Even as Charge Swells

Investors bid up the stock after the company adds once more to its diet-drug litigation reserve.

Trapped in the Wrong Stocks for the Ease?

If you are long Philip Morris, the utilities or drug stocks, listen up.

Two Steps Back, One and a Half Forward

With so many sectors sparkling, fewer stocks are hammered at every selloff, a nice holiday gift.

Insider Selling Has Some Wondering What's Next at American Home

Insider Selling Has Some Wondering What's Next at American Home

The drugmaker has been plagued by recalls and lawsuits, but its stock has jumped as tech swoons.

The Daily Screen: The Best Health Care Funds With Steady Managers

Only two funds made the cut.

What to Do About the Drugs

Different kinds of investors need different advice on this group. Cramer can speak to them all.

American Home Recalling Some Premarin Lots

American Home Recalling Some Premarin Lots

The company says no patients were affected by the recall of its top-selling drug, a hormone-replacement therapy.

American Home Says It's Happy on Its Own

American Home Says It's Happy on Its Own

But the drug maker says lawsuits over diet-drug cocktail Fen/Phen could drone on for 10 years.